KANT
Price
$0.34
Change
+$0.05 (+17.24%)
Updated
Jun 27 closing price
Capitalization
4.55M
MIST
Price
$1.94
Change
+$0.07 (+3.76%)
Updated
Jun 30, 04:59 PM (EDT)
Capitalization
99.44M
37 days until earnings call
Interact to see
Advertisement

KANT vs MIST

Header iconKANT vs MIST Comparison
Open Charts KANT vs MISTBanner chart's image
Kineta
Price$0.34
Change+$0.05 (+17.24%)
Volume$360
Capitalization4.55M
Milestone Pharmaceuticals
Price$1.94
Change+$0.07 (+3.76%)
Volume$1.71K
Capitalization99.44M
KANT vs MIST Comparison Chart in %
Loading...
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KANT vs. MIST commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KANT is a Hold and MIST is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (KANT: $0.34 vs. MIST: $1.86)
Brand notoriety: KANT and MIST are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KANT: 2% vs. MIST: 112%
Market capitalization -- KANT: $4.55M vs. MIST: $99.44M
KANT [@Biotechnology] is valued at $4.55M. MIST’s [@Biotechnology] market capitalization is $99.44M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KANT’s FA Score shows that 1 FA rating(s) are green whileMIST’s FA Score has 0 green FA rating(s).

  • KANT’s FA Score: 1 green, 4 red.
  • MIST’s FA Score: 0 green, 5 red.
According to our system of comparison, both KANT and MIST are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KANT’s TA Score shows that 4 TA indicator(s) are bullish while MIST’s TA Score has 5 bullish TA indicator(s).

  • KANT’s TA Score: 4 bullish, 3 bearish.
  • MIST’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both KANT and MIST are a good buy in the short-term.

Price Growth

KANT (@Biotechnology) experienced а +15.68% price change this week, while MIST (@Biotechnology) price change was +10.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.69%. For the same industry, the average monthly price growth was +32.93%, and the average quarterly price growth was +6.81%.

Reported Earning Dates

MIST is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+3.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIST($99.4M) has a higher market cap than KANT($4.55M). KANT YTD gains are higher at: -4.024 vs. MIST (-21.186). MIST has more cash in the bank: 56M vs. KANT (900K). KANT has less debt than MIST: KANT (710K) vs MIST (55.6M).
KANTMISTKANT / MIST
Capitalization4.55M99.4M5%
EBITDAN/A-48.18M-
Gain YTD-4.024-21.18619%
P/E RatioN/AN/A-
RevenueN/A0-
Total Cash900K56M2%
Total Debt710K55.6M1%
FUNDAMENTALS RATINGS
KANT vs MIST: Fundamental Ratings
KANT
MIST
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
56
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
5137
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KANT's Valuation (27) in the null industry is in the same range as MIST (56) in the Pharmaceuticals Major industry. This means that KANT’s stock grew similarly to MIST’s over the last 12 months.

KANT's Profit vs Risk Rating (100) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that KANT’s stock grew similarly to MIST’s over the last 12 months.

KANT's SMR Rating (100) in the null industry is in the same range as MIST (100) in the Pharmaceuticals Major industry. This means that KANT’s stock grew similarly to MIST’s over the last 12 months.

MIST's Price Growth Rating (37) in the Pharmaceuticals Major industry is in the same range as KANT (51) in the null industry. This means that MIST’s stock grew similarly to KANT’s over the last 12 months.

MIST's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as KANT (100) in the null industry. This means that MIST’s stock grew similarly to KANT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KANTMIST
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
88%
Bearish Trend 4 days ago
88%
Momentum
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
86%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 4 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 5 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 11 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
KANT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIST
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HLNFF13.24N/A
N/A
High Liner Foods Inc.
IMYSF32.46N/A
N/A
IMERYS SA
XNGSF8.36N/A
N/A
ENN Energy Holdings Ltd.
DMFG50.50N/A
N/A
Decker Manufacturing Corp.
ORBT3.45-0.05
-1.43%
Orbit International Corp.

KANT and

Correlation & Price change

A.I.dvisor tells us that KANT and NCNA have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KANT and NCNA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KANT
1D Price
Change %
KANT100%
+15.88%
NCNA - KANT
24%
Poorly correlated
N/A
CNSP - KANT
24%
Poorly correlated
+5.02%
ABUS - KANT
22%
Poorly correlated
-2.19%
MIST - KANT
22%
Poorly correlated
-1.59%
JAZZ - KANT
22%
Poorly correlated
-0.57%
More

MIST and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIST has been loosely correlated with EQ. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MIST jumps, then EQ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIST
1D Price
Change %
MIST100%
-1.59%
EQ - MIST
45%
Loosely correlated
N/A
KRYS - MIST
36%
Loosely correlated
-2.60%
ETNB - MIST
32%
Poorly correlated
-0.90%
JBPHF - MIST
31%
Poorly correlated
N/A
GYRE - MIST
29%
Poorly correlated
+0.54%
More